← Back to Search

Oxytocic Agent

Carbetocin 50 mcg for Uterine Atony

Phase 4
Waitlist Available
Led By Julie Bédard
Research Sponsored by Laval University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

The purpose of this study is to evaluate the effectiveness of two doses of carbetocin (50 mcg vs 100 mcg) in preventing uterine atony during elective cesarean section.

Eligible Conditions
  • Uterine Atony
  • Postpartum Hemorrhage

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Carbetocin 50 mcgExperimental Treatment1 Intervention
Group II: Carbetocin 100 mcgActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carbetocin
FDA approved

Find a Location

Who is running the clinical trial?

Laval UniversityLead Sponsor
423 Previous Clinical Trials
172,956 Total Patients Enrolled
Julie BédardPrincipal InvestigatorLaval University
~5 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top